Immune checkpoints have become of great importance as a therapeutic target in NSCLC, with several anti PD-1 and anti PD-L1 agents being successfully tested and approved by regulatory drug agencies [65,66,67,68,69]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.